Clinical Trial Update: CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms [Phase 1]

View source ↗

Summary

Phase 1 trial of CD19-targeted CAR T cells for refractory/relapsed CD19-positive B-cell neoplasms (ALL, mantle cell lymphoma, diffuse large B-cell lymphoma) is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• CD19-targeted CAR T cells

Snippet

Sponsor: FamiCordTx | Conditions: Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) | Phase 1 | Status: RECRUITING